Key trends to watch

The trends shaping drug development and
patient health outcomes in 2023 and beyond

Download the report

The life science industries have tamed COVID-19. Now, they must continue to replenish pipelines with innovative treatments.

Fortunately, pharmas and biotechs are making rapid progress toward personalized medicine. Meanwhile, an enormous market for biologics is opening up in Mainland China. However, these industries have work to do in addressing underserved conditions and populations.

The growing market in Mainland China

 

We identified nine drugs that are likely to achieve the traditional $1 billion blockbuster status in Mainland China by 2030, including both global and domestically manufactured assets.

The impending loss of exclusivity of HUMIRA

 

All eyes will be on the expiry of a key U.S. patent covering AbbVie’s HUMIRA® (adalimumab) in 2023, which could see HUMIRA biosimilars launching in the United States throughout the year.

COVID-19 vaccines and therapies

 

Although attention on COVID-19 vaccine and therapeutic development has waned since the height of the pandemic, research activity remains steady as the industry tries to stay ahead of new variants, continue to reduce COVID-19-related hospitalizations and mortality and grapple with ‘long COVID.’

Personalized medicines move from promise to reality

 

2023 marks the 25th anniversary of the approval of Herceptin®, which changed the diagnosis of HER2+ breast cancer from a death sentence to one of hope thanks to Herceptin’s ability to target HER2.

Sustainable goals encourage innovative solutions

 

Since their introduction in 2015, the United Nations Sustainable Development Goals (SDGs) have achieved global adoption across industries, with many life sciences companies, such as Novo Nordisk, GSK plc, Pfizer and AstraZeneca, incorporating them into their environmental, social and governance plans.

Related content

Walking the talk on patient centricity
An actionable and measurable model for life science companies to involve and empower the people that use their products
Article 

Mainland China’s NRDL: The expensive yet priceless ticket to market access
REPORT

Realizing telehealth’s potential to reduce healthcare disparities:

From innovation to bottom line

Access global intelligence, advanced analytics and global experts from Clarivate.

Contact our team